Margus Viigimaa

74.0k total citations · 1 hit paper
83 papers, 1.2k citations indexed

About

Margus Viigimaa is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Margus Viigimaa has authored 83 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Cardiology and Cardiovascular Medicine, 25 papers in Surgery and 14 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Margus Viigimaa's work include Blood Pressure and Hypertension Studies (21 papers), Cardiovascular Health and Disease Prevention (14 papers) and Lipoproteins and Cardiovascular Health (13 papers). Margus Viigimaa is often cited by papers focused on Blood Pressure and Hypertension Studies (21 papers), Cardiovascular Health and Disease Prevention (14 papers) and Lipoproteins and Cardiovascular Health (13 papers). Margus Viigimaa collaborates with scholars based in Estonia, Italy and Czechia. Margus Viigimaa's co-authors include Alexandros Sachinidis, Maria Toumpourleka, Konstantinos Koutsampasopoulos, Tiina Titma, Kalju Meigas, Kristjan Pilt, В. З. Ланкин, А. К. Тихазе, Г. Г. Коновалова and Krzysztof Narkiewicz and has published in prestigious journals such as Journal of the American College of Cardiology, International Journal of Molecular Sciences and European Heart Journal.

In The Last Decade

Margus Viigimaa

73 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Macrovascular Complications of Type 2 Diabetes Mellitus

2019 241 citations Margus Viigimaa et al. profile →

Peers

Countries citing papers authored by Margus Viigimaa

Since Specialization

Citations

This map shows the geographic impact of Margus Viigimaa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Margus Viigimaa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Margus Viigimaa more than expected).

Fields of papers citing papers by Margus Viigimaa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Margus Viigimaa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Margus Viigimaa. The network helps show where Margus Viigimaa may publish in the future.

Co-authorship network of co-authors of Margus Viigimaa

This figure shows the co-authorship network connecting the top 25 collaborators of Margus Viigimaa. A scholar is included among the top collaborators of Margus Viigimaa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Margus Viigimaa. Margus Viigimaa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Hypertension Excellence Centre programme of the European Society of Hypertension – current status, activities and reshaping for the future 2023 ·Blood Pressure ·Thomas Weber, Michael Doumas, Christian Delles, Bojan Jelaković, Margus Viigimaa, Krzysztof Narkiewicz, Andrzej Januszewicz, Reinhold Kreutz, Guıdo Grassı, Giuseppe Mancia	1
2	Effectiveness and feasibility of cardiovascular disease personalized prevention on high polygenic risk score subjects: a randomized controlled pilot study 2022 ·European Heart Journal Open ·Margus Viigimaa, Mikk Jürisson, Heti Pisarev, Ruth Kalda, Helene Alavere, Alar Irs, Aet Saar, Krista Fischer, Kristi Läll, (unknown), Nina Mars, Elisabeth Widén, Samuli Ripatti, Andres Metspalu	7
3	Evaluation of a new semi-automated Hydragel 11 von Willebrand factor multimers assay kit for routine use 2020 ·Journal of Medical Biochemistry ·(unknown), Tímea Szántó, Margus Viigimaa, Sandra Lejniece, (unknown), (unknown), (unknown)	8
4	Hypertension and Reproduction 2020 ·Current Hypertension Reports ·Peter M. Nilsson, Margus Viigimaa, Aleksander Giwercman, Renata Cífková	25
5	The role of red yeast rice (RYR) supplementation in plasma cholesterol control: A review and expert opinion 2019 ·Atherosclerosis Supplements ·Maciej Banach, Éric Bruckert, Olivier Descamps, Lars Ellegård, М. В. Ежов, Bernhard Föger, Zlatko Fras, Petri T. Kovanen, Gustavs Latkovskis, Winfried März, Demosthenes B. Panagiotakos, György Paragh, Daniel Pella, Angela Pirillo, Andrea Poli, Željko Reiner, Günther Silbernagel, Margus Viigimaa, Michal Vráblík, Alberico L. Catapano	39
6	Digital Health in Cardiology: The Estonian Perspective 2019 ·Cardiology ·(unknown), Margus Viigimaa	9
7	The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease 2019 ·Current Pharmaceutical Design ·Panteleimon Pantelidis, Michail Sideris, Margus Viigimaa, (unknown), Pavlos Deligkaris, Ioanna Zografou, Dragan Lović	7
8	PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases 2018 ·Terapevticheskii arkhiv ·В. З. Ланкин, А. К. Тихазе, Margus Viigimaa, И Е Чазова	10
9	Photoplethysmographic signal rising front analysis for the discrimination of subjects with increased arterial ageing; pp. 309–314 2014 ·Proceedings of the Estonian Academy of Sciences ·Kristjan Pilt, Kalju Meigas, (unknown), Margus Viigimaa	9
10	The initiation of free radical peroxidation of low-density lipoproteins by glucose and its metabolite methylglyoxal: a common molecular mechanism of vascular wall injure in atherosclerosis and diabetes 2014 ·Molecular and Cellular Biochemistry ·В. З. Ланкин, Г. Г. Коновалова, А. К. Тихазе, К. Б. Шумаев, (unknown), Margus Viigimaa	45
11	Identification of the hemodynamic modulators and hemodynamic status in uncontrolled hypertensive patients 2013 ·Blood Pressure ·Margus Viigimaa, (unknown), Wiktoria Wojciechowska, Kalina Kawecka−Jaszcz, Ingrid Toft, George S. Stergiou, E G Nasothimiou, Vasilios Kotsis, Enrico Agabiti Rosei, Massimo Salvetti, Maria Dorobanţu, Nieves Martell‐Claros, (unknown), R Hernández-Hernández, Mónica Doménech, António Coca	6
12	Cholesterol-rich low density lipoproteins are also more oxidized 2011 ·Molecular and Cellular Biochemistry ·В. З. Ланкин, Margus Viigimaa, А. К. Тихазе, (unknown), Г. Г. Коновалова, (unknown), (unknown), (unknown), (unknown), (unknown)	15
13	Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease 2011 ·Clinical Biochemistry ·H Vaverková, Michel Farnier, Maurizio Averna, Luc Missault, Margus Viigimaa, Qian Dong, Arvind Shah, Amy O. Johnson‐Levonas, Philippe Brudi	2
14	Malondialdehyde-modified low-density lipoproteins as biomarker for atherosclerosis 2010 ·Blood Pressure ·Margus Viigimaa, (unknown), (unknown), А. К. Тихазе, Г. Г. Коновалова, (unknown), В. З. Ланкин	39
15	Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study 2010 ·European Heart Journal ·Guıdo Grassı, Renata Cífková, Stéphane Laurent, Krzysztof Narkiewicz, (unknown), Csaba Farsang, Margus Viigimaa, Serap Erdine, Gianmaria Brambilla, Michele Bombelli, Raffaella Dell’Oro, (unknown), Giuseppe Mancia	63
16	Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of Hypertension 2010 ·Journal of Hypertension ·George S. Stergiou, Martin G. Myers, John L. Reid, Michel Burnier, Krzysztof Narkiewicz, Margus Viigimaa, Giuseppe Mancia	8
17	Resequencing PNMTin European hypertensive and normotensive individuals: no common susceptibilily variants for hypertension and purifying selection on intron 1 2007 ·BMC Medical Genetics ·(unknown), Peeter Juhanson, Viktor Kožich, Mai Ots, Margus Viigimaa, Maris Laan	13
18	Risk factors for coronary heart disease in 55‐ and 35‐year‐old men and women in Sweden and Estonia 2002 ·Journal of Internal Medicine ·Jan Johansson, Margus Viigimaa, Mats Jensen‐Urstad, Ingvar Krakau, Lotta Hansson	11
19	Platelet Aggregation, Thromboxane A₂, Prostacyclin Generation and Platelet Sensitivity to Prostacyclin during the First Month after Myocardial Infarction 1995 ·Platelets ·Margus Viigimaa, (unknown), (unknown), (unknown), Rein Teesalu	1
20	Antiaggregative Therapy with Acetylsalicylic Acid and Diclofenac in Patients with Acute Myocardial Infarction 1994 ·Upsala Journal of Medical Sciences ·Margus Viigimaa, (unknown), (unknown), (unknown), Rein Teesalu	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact